Latest news

• AbbVie sales jump on strong Humira gains

  AbbVie's sales gains came despite the continuing impact of the loss of patent protection for cholesterol-lowering drug TriCor (fenofibrate), which fell 66 per cent to $153m as generic competition

• AbbVie said to be planning major salesforce cuts in US

  start of generic competition to cholesterol-lowering drugs TriCor (fenofibrate) and Niaspan (niacin). ... According to AbbVie's 2012 report, combined sales of TriCor and Trilipix totalled $1.1bn, while Niaspan contributed $911m, with all sales derived

• Abbott reports flat Q2 net profit

  Cholesterol treatment, TriCor/Trilipix (fenofibrate) also saw improved growth, with sales increasing 15.6 per cent to £388m.

• Abbott to purchase Solvay pharma

  TriCor uses the active ingredient fenofibrate and accounts for about 20 per cent of Brussels-based Solvay's pharmaceutical sales. ... In 2011 TriCor faces generic competition and Abbott is seeking regulatory approval to market TriLipix in combination

• Elan and J&JPRD submit NDA for novel Invega reformulation

  Four US marketed products currently use NanoCrystal Technology: lipid-lowering TriCor (fenofibrate), which is marketed by Abbott and Solvay; cachexia treatment Megace ES (megestrol), which is marketed by Par Pharmaceutical; immunosuppressant